905994-07-2

Usage

Uses

Since the provided materials do not specify any particular uses for C₂₈H₃₅FN₄O₈S, it is not possible to list its applications based on the given information. However, given its complex structure and the presence of various functional groups, it is likely that C₂₈H₃₅FN₄O₈S could have potential applications in various industries, such as pharmaceuticals, materials science, or chemical research, depending on its specific properties and characteristics. Further investigation and research would be required to determine the exact uses and applications of C₂₈H₃₅FN₄O₈S.

Upstream product

• 159622-10-3 (1R,2S)-1-(tert-butoxycarbonylamino)-2-vinylcyclopropanecarboxylic acid 
• 259217-95-3 N-Boc-(1R,2S)-1-amino-2-vinylcyclopropane carboxylic acid ethyl ester 
• 1374041-49-2 C₁₇H₂₂BrNO₅ 
• 1374041-50-5 C₂₆H₂₈BrFN₂O₆ 
• 630421-48-6 tert-butyl ((1R,2S)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclopropyl)carbamate 
• 1013925-90-0 (2S,4R)-4-(4-fluoro-1,3-dihydro-isoindole-2-carbonyloxy)-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 
• 13726-69-7 (2S,4R)-4-hydroxy-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid 
• 154350-29-5 cyclopropanesulphonamide 
• 1152020-87-5 C₂₅H₃₀FN₃O₇ 
• 127168-78-9 4-fluoro-2,3-dihydro-1H-isoindole 

Relevant academic research and scientific papers

HCV NS3 PROTEASE INHIBITORS

The present invention is directed to compounds, compositions and methods for treating or preventing HCV viral infections in human patients or other animal hosts.

NOVEL SPECIFIC HCV NS3 PROTEASE INHIBITORS

The present invention is directed to compounds, compositions and methods for treating or preventing viral infections, in particular, HCV in human patients or other animal hosts.

HYDROXYAMIC ANALOGS AS HEPATITIS C VIRUS SERINE PROTEASE INHIBITOR

The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the c

HCV PROTEASE INHIBITORS AND USES THEREOF

The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

Hepatitis C virus inhibitors

The present disclosure is generally directed to antiviral compounds, and more specifically directed to compounds which inhibit the function of the NS3 protease (also referred to herein as “serine protease”) encoded by Hepatitis C virus (HCV), compositions comprising such compounds, and methods for inhibiting the function of the NS3 protease.